-
19 Décembre 2025
-
19 Décembre 2025
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia os...
-
16 Avril 2025
-
16 Avril 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full...
-
20 Mai 2024
- 4 mn de lecture
-
20 Mai 2024
- 4 mn de lecture
Improving Diversity in Research and Development to Drive Health Equity
To mark World Clinical Trials Day, we sat down with Christelle Huguet, Executive Vice President, Head of R&D at Ipsen to explore the importance of diversity from all sides of the research and development process, as we accelerate innovation. ...
-
13 Février 2025
-
13 Février 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
PARIS, FRANCE, 13 February 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024....
-
29 Juin 2023
-
29 Juin 2023
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effect...
-
29 Août 2023
- 2 mn de lecture
-
29 Août 2023
- 2 mn de lecture
Learning the impacts of FOP from patients and their families – The Burden of Illness study
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder where extra bone formation takes place in soft tissues, including muscles, tendons and ligaments, causing irreversible and progressive loss of mobility, leading to severe disabil...
-
16 Août 2023
-
16 Août 2023
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossific...
-
29 Août 2023
- 2 mn de lecture
-
29 Août 2023
- 2 mn de lecture
Putting yourself in the shoes of someone with an ultra-rare condition: the first FOP immersive experience
You can never truly understand what it’s like to live with an ultra-rare condition unless you’ve experienced it for yourself. With this in mind, we recently embarked on a project to help healthcare professionals experience what it’s like to live with...
-
24 Août 2023
-
24 Août 2023
Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio
Paris and Montréal, 25 February 2019 – Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage ...
-
12 Février 2026
-
12 Février 2026
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
PARIS, FRANCE, 12 February 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year (FY) 2025 and for the fourth quarter of 2025....